NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the first patient has been treated in a Phase 1b proof-of-concept, open-label st
Moving Average Crossover Alert: Sorrento Therapeutics (SRNE)
09:24am, Wednesday, 05'th May 2021
Sorrento Therapeutics (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Over the last several months, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and its development partners have advanced into clinical development
SRNE Stock: 10.67% Increase Explanation
06:59pm, Monday, 26'th Apr 2021
The stock price Sorrento Therapeutics Inc (NASDAQ: SRNE) increased by 10.67% today. This is why it happened.
Why Sorrento Therapeutics Stock Is Soaring Today
02:04pm, Monday, 26'th Apr 2021
Hint: It's not because of anything the company said or did.
Sorrento's Human Derived Mesenchymal Stem Cells Achieves 100% Discharge Rate In Critically-Ill COVID-19 Patients
09:51am, Tuesday, 20'th Apr 2021
Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced data from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute
Sorrento Therapeutics Stock Looks To Form Bullish Falling Wedge
04:42pm, Monday, 12'th Apr 2021
Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares lost ground Monday with no evident explanation. The stock was trending on StockTwits.
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between 2 San Diego-China Oncology Biopharmas
11:55pm, Sunday, 11'th Apr 2021
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Sorrento will pay $38 million upfront in stock and make up to an additional $450 million in milestones payments
Sorrento Therapeutics Is Still A Buy
12:06pm, Sunday, 11'th Apr 2021
Sorrento Therapeutics recently announced the acquisition of ACEA Therapeutics. ACEA's acquisition brings to Sorrento the late clinical-stage Abivertinib.
Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion
03:00pm, Friday, 09'th Apr 2021
PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental n
Vir Biotechnology vs. Sorrento Therapeutics: The Wisdom of Crowds Says.
06:00am, Thursday, 08'th Apr 2021
Which stock has more potential for growth over the next year? Let's look to the stars for an answer.
7 Pharmaceutical Stocks That Could Get a Covid Hangover
05:01am, Thursday, 01'st Apr 2021
Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared f
New Strong Sell Stocks for March 31st
09:51am, Wednesday, 31'st Mar 2021
AROW, BGS, KEX, SRNE, and TOSYY have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2021
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
03:58pm, Thursday, 25'th Mar 2021
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today updated positive results from its Phase 1b study of human allogeneic ad
Take Your Profits! 7 Covid Winners to Sell Now
11:36am, Tuesday, 23'rd Mar 2021
Because of the pandemic, many so-called Covid stocks enjoyed outsized gains but investors might want to consider trimming their exposure. The post Take Your Profits!
